The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N'-cyano-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-N-[2-(methyloxy)ethyl]morpholine-4-carboximidamide ID: ALA3986102
PubChem CID: 57802864
Max Phase: Preclinical
Molecular Formula: C25H27Cl2N7O4
Molecular Weight: 560.44
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: COCCN/C(=N\C#N)N1CCOC(COc2cc3ncnc(Nc4ccc(Cl)c(Cl)c4)c3cc2OC)C1
Standard InChI: InChI=1S/C25H27Cl2N7O4/c1-35-7-5-29-25(30-14-28)34-6-8-37-17(12-34)13-38-23-11-21-18(10-22(23)36-2)24(32-15-31-21)33-16-3-4-19(26)20(27)9-16/h3-4,9-11,15,17H,5-8,12-13H2,1-2H3,(H,29,30)(H,31,32,33)
Standard InChI Key: ALVFQMWHUJBCDD-UHFFFAOYSA-N
Molfile:
RDKit 2D
38 41 0 0 0 0 0 0 0 0999 V2000
33.7120 -19.2506 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
34.4240 -18.8448 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.4197 -18.0194 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
33.7108 -17.6158 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.0024 -18.8414 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.0059 -18.0275 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2994 -17.6182 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5929 -18.0253 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5921 -18.8452 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2987 -19.2517 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.8839 -17.6167 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
30.8872 -19.2538 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
33.7108 -16.7945 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
34.4137 -16.3871 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1211 -16.7971 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8294 -16.3846 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8248 -15.5651 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1140 -15.1619 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.4087 -15.5734 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.1792 -18.8458 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.4718 -19.2550 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.7672 -18.8424 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.0620 -19.2481 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
28.0584 -20.0657 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.7663 -20.4758 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.4778 -20.0685 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
27.3555 -18.8374 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.5391 -16.7898 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
36.5298 -15.1518 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
30.1765 -18.0259 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.3578 -18.0203 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.6465 -19.2440 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
25.9400 -18.8333 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.6513 -17.6096 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.6537 -16.7924 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.9472 -16.3817 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
25.9496 -15.5645 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.2335 -18.4236 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5 1 1 0
1 2 2 0
2 3 1 0
3 4 2 0
4 6 1 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 10 1 0
10 5 2 0
8 11 1 0
9 12 1 0
4 13 1 0
13 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 14 1 0
12 20 1 0
20 21 1 0
21 22 1 0
21 26 1 0
22 23 1 0
23 24 1 0
24 25 1 0
25 26 1 0
23 27 1 0
16 28 1 0
17 29 1 0
11 30 1 0
27 31 1 0
27 32 2 0
32 33 1 0
31 34 1 0
34 35 1 0
35 36 1 0
36 37 1 0
33 38 3 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 560.44Molecular Weight (Monoisotopic): 559.1502AlogP: 3.84#Rotatable Bonds: 9Polar Surface Area: 126.15Molecular Species: NEUTRALHBA: 9HBD: 2#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 2#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 4.96CX LogP: 3.76CX LogD: 3.76Aromatic Rings: 3Heavy Atoms: 38QED Weighted: 0.17Np Likeness Score: -1.28
References 1. (2009) Receptor-type kinase modulators and methods of use,